Guideline on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIg)

| Adoption by CHMP for release for consultation | 15 December 2016 |
| Start of public consultation | 1 January 2017 |
| End of consultation (deadline for comments) | 31 March 2017 |
| Agreed by Blood Products Working Party | 14 June 2018 |
| Adoption by CHMP | 28 June 2018 |
| Date of coming into effect | 1 January 2019 |
| Draft agreed by Blood Products Working Party | 8 June 2020 |
| Adopted by CHMP for release for consultation | 17 September 2020 |
| Start of public consultation | 13 October 2020 |
| End of consultation (deadline for comments) | 13 January 2020 |
| Revised draft agreed by the Blood Products Working Party | 29 October 2021 |
| Adopted by CHMP for release for consultation | 16 December 2021 |
| Date of coming into effect | 1st January 2022 |

This guideline replaces Guideline on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIg) (EMA/CHMP/BPWP/94033/2007 rev. 3)
<table>
<thead>
<tr>
<th>Keywords</th>
</tr>
</thead>
<tbody>
<tr>
<td>IVIg, human normal immunoglobulin, primary and secondary immunodeficiency syndromes, hypogammaglobulinaemia, primary immune thrombocytopenia (= idiopathic thrombocytopenic purpura) (ITP), Guillain-Barré syndrome, Kawasaki’s disease, multifocal motor neuropathy (MMN), chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), measles pre-/post exposure prophylaxis.</td>
</tr>
</tbody>
</table>
Guideline on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIg)

Table of contents

Executive summary ........................................................................................................................................ 4
1. Introduction ............................................................................................................................................... 4
2. Scope ..................................................................................................................................................... 4
3. Legal basis and relevant guidelines ....................................................................................................... 5
4. Background ........................................................................................................................................... 5
5. Product for which an application for a marketing authorisation is to be submitted: “New products” ................................................................................................................................. 6
  5.1. Biological data ..................................................................................................................................... 6
  5.1.1. Biological characteristics ................................................................................................................. 6
  5.1.2. Biological activity ............................................................................................................................ 6
  5.2. Pharmacokinetics ............................................................................................................................... 7
  5.2.1. PK parameters ............................................................................................................................... 7
  5.2.2. PK population ............................................................................................................................... 7
  5.2.3. PK study chart ................................................................................................................................ 8
  5.3. Efficacy ............................................................................................................................................... 8
  5.3.1. Replacement therapy in primary immunodeficiency syndromes ..................................................... 8
  5.3.2. Replacement therapy in secondary immunodeficiencies ................................................................. 9
  5.3.3. ITP ................................................................................................................................................ 9
  5.3.4. Measles pre-/post exposure prophylaxis ......................................................................................... 10
  5.3.5. Guillain-Barré syndrome (GBS), Kawasaki’s disease, Multifocal motor neuropathy (MMN), Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) ................................................................................. 10
  5.3.6. Other indications ......................................................................................................................... 11
  5.4. Safety ................................................................................................................................................. 11
  5.5. Adverse events .................................................................................................................................. 11
  5.6. Safety with respect to transmissible agents ..................................................................................... 11
  5.6.1. Viral Safety ................................................................................................................................... 11
  5.6.2. Other transmissible agents ........................................................................................................... 12
  5.6.3. Other safety issues ....................................................................................................................... 12
  5.7. Studies in paediatric patients ........................................................................................................... 12
6. Change in the manufacturing process of authorised products ................................................................. 12
  6.1. General aspects ................................................................................................................................ 12
  6.2. Biological data .................................................................................................................................. 13
  6.3. Pharmacokinetics ............................................................................................................................. 13
  6.4. Efficacy and safety ............................................................................................................................ 13
7. References .............................................................................................................................................. 14
Definitions ....................................................................................................................................................... 14
Executive summary

This Guideline describes the information to be documented when an application is made for a marketing authorisation for a human normal immunoglobulin for intravenous use (IVIg). The guidance covers biological data, clinical trials and patient follow-up. Quality aspects are outside the scope of this guideline.

Guidance is also provided for authorised products where a significant change in the manufacturing process has been made.

This is the fourth revision of the Guideline on the clinical investigation of human normal immunoglobulin for intravenous administration (EMA/CHMP/BPWP/94033/2007 rev. 3). It replaces Version 3 and provide recommendation to use immunoglobulins for measles pre-/post exposure prophylaxis for susceptible persons in whom active immunisation is contraindicated or not advised.

1. Introduction

The purpose of this Guideline is to provide applicants and regulators with harmonised guidance for applications for marketing authorisation for IVIg.

The first use of polyvalent immunoglobulin preparations was as replacement therapy in humoral immunodeficiency situations. As human normal immunoglobulin for intravenous use (IVIg) is prepared from plasma collected from a high number of healthy blood and plasma donors, the spectrum of antibody specificity expressed by the IgG is large. Among the antibody specificity spectrum, IVIg recognises a large number of bacterial, viral and other infectious agent antigens, and also a large number of self-antigens. The therapeutic effect in replacement covers primary immunodeficiencies (PID) and a number of secondary immunodeficiencies (SID). IVIg has also been used in a clinical setting for its immunomodulatory activity. The immunomodulatory indications for IVIgs based on clinical trials with various IVIg products are primary immune thrombocytopenia (ITP), Guillain–Barré syndrome (GBS), Kawasaki’s disease, multifocal motor neuropathy (MMN), and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). This guideline also provides recommendation in relation to immunoglobulins intended for measles pre-/post exposure prophylaxis for susceptible persons in whom active immunisation is contraindicated or not advised.

2. Scope

This guideline describes the information to be documented when an application for a marketing authorisation for IVIg is made, including biological data, pharmacokinetics, clinical trials and patient follow-up.

These data are required for:
1. products for which an application for a marketing authorisation is to be submitted, referred to as “new products” in the text and
2. authorised products where a significant change in the manufacturing process has been made (e.g. additional viral inactivation/removal steps or new purification procedures).

This Guideline covers normal human immunoglobulin for intravenous administration defined by the European Pharmacopoeia monograph 0918. The Guideline does not relate to fragmented or chemically modified products.

Quality aspects are also outside the scope of this guideline.
3. **Legal basis and relevant guidelines**

This Guideline should be read in conjunction with the introduction and general principles (4) and part I of the Annex I to Directive 2001/83 as amended and the following guidance documents.

- Guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg) (EMA/CHMP/BPWP/94038/2007)
- Guideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg) (EMA/CHMP/BPWP/410415/2011)
- Core SmPC for human normal immunoglobulin for subcutaneous and intramuscular use (EMA/CHMP/BPWP/143744/2011 current version)
- Guideline on plasma-derived medicinal products (EMA/CHMP/BWP/706271/2010).
- Guideline on good pharmacovigilance practices, Module V – Risk management systems (EMA/838713/2011)
- Guideline on “Comparability of Biotechnological Products (ICH Q5E, CPMP/ICH/5721/03)

4. **Background**

Biological data, pharmacokinetic data and clinical evidence of **efficacy and safety in primary/secondary humoral immunodeficiencies and ITP** are the key elements required for the licensing of IVIg in the following claimed indications:

IVIg can be used in all age ranges, unless otherwise specified below.

**Replacement therapy in:**
- Primary immunodeficiency syndromes (PID) with impaired antibody production.
- Secondary immunodeficiencies (SID) in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure (PSAF)* or serum IgG level of <4 g/L.

* PSAF = failure to mount at least a 2-fold rise in IgG antibody titre to pneumococcal polysaccharide and polypeptide antigen vaccines

**Immunomodulation in:**
- Primary immune thrombocytopenia¹ (ITP) in patients at high risk of bleeding or prior to surgery to correct the platelet count
- Guillain-Barré Syndrome (GBS)
- Kawasaki’s disease
- Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
- Multifocal motor neuropathy (MMN)

¹ The term idiopathic thrombocytopenic purpura has been exchanged for primary immune thrombocytopenia according to the recommendations of an International Working Group (IWG) in "Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children". The acronym will remain the same.
In other indications, relevant clinical data are required, see 5.3.6.

5. Product for which an application for a marketing authorisation is to be submitted: “New products”

5.1. Biological data

Adequate documentation with regards batch-to-batch consistency must be provided in Module 3 of the dossier and should follow the Ph. Eur. Monograph 0918 requirements.

However, specific data are needed to support the pharmacodynamic and therapeutic activities as well as the safety profile of the IVIg preparation. The data should include the following parameters and be summarised in Module 5 of the dossier along with the cross-reference to Module 3 (wherever applicable).

5.1.1. Biological characteristics

General

- Molecular size distribution: quantification of monomers, dimers, fragments, polymers and aggregates.

- Impurities (proteins -IgA, IgM, IgE, - other).

For pharmacodynamic and therapeutic activity

- Distribution of IgG subclasses

- Content of clinically relevant antibodies to:
  - bacteria, such as: C. diphtheriae; H. influenzae type B; S. pneumoniae, S. pyogenes.
  - viruses, such as: hepatitis A and B viruses; cytomegalovirus; varicella-zoster virus; rubella virus; parvovirus B19; poliomyelitis virus type I; measles virus (for details on measles virus pre-/post-exposure prophylaxis see 5.3.4.).

Other

- Anti-complementary activity

- Anti-A and anti-B haemagglutinins

- Haemolysins (usually anti-A and anti-B)

- Anti-D antibodies

- Prekallikrein activator.

5.1.2. Biological activity

- In vivo and/or in vitro quantification of neutralising antibodies (depending on the claimed neutralising activities).

- Fab and Fc functions (functional integrity): antigen-driven complement fixation, opsonisation, phagocytosis, antibody-dependent cell-mediated cytotoxicity (ADCC).

- Immunomodulatory and anti-inflammatory activities for auto-immune diseases, depending on the claimed indications and the relevance of in vitro and/or in vivo models such as:
o Ability to inhibit auto-antibody activity \textit{in vitro}

o Experimental autoimmune models.

\textbf{5.2. Pharmacokinetics}

\textbf{5.2.1. PK parameters}

1. Given that 40 patients with PID are recommended to be included for efficacy evaluation (see below), it is recommended that IgG trough levels are studied in the same 40 patients, whereby 20 of these should be children or adolescents with an age distribution representative of the intended patient population. The IgG trough levels of the investigational product should be assessed prior to each infusion over a period of 6 months, starting after 5–6 administrations of the product. The IgG trough levels obtained and treatment intervals should be compared to either the trough levels and treatment intervals of the former product (in previously treated patients) or to literature data (in patients naïve to IVIg treatment), whereby predefined comparability limits should be justified by the applicant.

2. Other PK parameters including plasma concentration-time curve, half-life, area under the curve, volume of distribution, Cmax, Tmax, and elimination rate constant(s) should be measured in approximately 20 adult PID patients assessed by repeated blood sampling after approximately 5–6 administrations of the product until immediately before the next infusion. The other PK parameters obtained should be discussed by the applicant in the light of the literature data.

\textbf{5.2.2. PK population}

Pharmacokinetic data set can be derived from patients with PID who are either already stabilised on IVIg treatment (group A) or naïve to IVIG treatment (group B) or the set can contain both patient groups.

Group A) Patients already stabilised on IVIg treatment

In patients already stabilised with another IVIg preparation, trough levels and treatment intervals should be documented for at least two previous infusions, prior to the introduction of the new IVIg preparation. After a period of approximately 5–6 administrations of the new IVIg product, trough levels and treatment intervals should be measured.

Group B) Patients naïve to IVIg treatment

In patients naïve to IVIg the pharmacokinetic profile should be assessed when steady state (Tss) is reached.
5.2.3. PK study chart

Stabilised PID patients ≥2 infusions of previous IVIg + IgG trough levels

A

40 PID patients (20 children)

B

Naïve PID patients

Administration of new IVIg

40 patients: IgG trough levels

20 adult patients: other PK data

5.3. Efficacy

IVIg is used as replacement therapy for the treatment of primary and secondary immunodeficiencies.

5.3.1. Replacement therapy in primary immunodeficiency syndromes

Efficacy should be demonstrated in an open label, single-arm clinical trial of one-year duration in PID. The patients’ selection should take into account statistical considerations (see below).

At least 40 patients should be included; approximately half of these patients should be children and adolescents with an age distribution representative of this patient population. The patients should be followed over 12 months to avoid a seasonal bias (due to a greater rate of infections in the winter months).

The recommended primary endpoint is the number of serious bacterial infections per patient per year – see statistical considerations below). The protocol should prospectively provide specific diagnostic criteria for each type of serious infection to be included in the primary efficacy analysis. Serious bacterial infections include:

- bacteraemia or sepsis,
- bacterial meningitis,
- osteomyelitis / septic arthritis,
- bacterial pneumonia,
- visceral abscess.

Secondary endpoints are PK parameters, e.g. IgG trough levels (see section 5.2. ), all other infections, antibiotic treatment, days lost from school/work, hospitalisations and fever episodes.

Statistical considerations

The study primary efficacy objective should be to demonstrate that in treated patients, the rate of acute serious bacterial infections is less than 1.0 per person per year. Although the sample size and power calculation is at the applicant’s discretion and must be justified, the following is recommended: The number of patients to be included into the study is expected to exceed 40 patients so that the study provides at least 80% power to reject the null-hypothesis of an acute serious bacterial infection.
rate (infection per patient per year) greater or equal to 1.0 by means of a one-sided test and a Type I error of 0.01.

The secondary endpoints should be prospectively defined and their statistical analyses provided in the study protocol.

The efficacy results from this study would apply to all types of primary immunodeficiency syndromes due to deficiency of functional IgG.

### 5.3.2. Replacement therapy in secondary immunodeficiencies

SID in patients who suffer from severe or recurrent bacterial infections, ineffective antibiotic treatment and either proven specific antibody failure (PSAF)* or serum IgG level of <4 g/l.

* PSAF= failure to mount at least a 2-fold rise in IgG antibody titre to pneumococcal polysaccharide and polypeptide antigen vaccines.

The above indication would be granted as long as efficacy has been proven in primary immunodeficiency syndromes (see 5.3.1).

### 5.3.3. ITP

IVIg is used for the treatment of ITP in children, adolescents or adults at high risk of bleeding or prior to surgery to correct the platelet count.

There are no data to support the equivalence of different IVIg preparations, especially with regards to immunomodulatory activities. Thus, a clinical efficacy study is required to establish the product efficacy in this indication.

**Efficacy study design**

An open-label study of approximately 4 weeks duration with the investigational IVIg should be performed in approximately 30 chronic (> 12 months duration) adult ITP patients with a baseline platelet count of <30 x 10^9/l. Whilst this sample size was selected primarily based on feasibility considerations, taking into account patient availability, data show that results appear comparable between products (except for Fc modified products) based on this sample size. For consistency purposes, applicants are recommended to continue to use this sample size facilitate comparisons to results from previous studies taking into account any potential differences between studies (e.g. response criteria definitions referred below). Any other sample size should be justified by the applicant.

Standard doses should be studied (0.8 – 1 g/kg on day one, which may be repeated once within 3 days, or 0.4 g/kg/day for 2–5 days). If other dosage regimens are applied for, they should be supported by clinical data.

Baseline data on splenectomy and co-medication (especially affecting bleeding or platelets) should be provided. Patients included in the study may have refractory ITP i.e. the failure to achieve a response or loss of response after splenectomy and the need of treatment(s) to minimize the risk of bleeding considered as clinically significant by the investigator. In clinical practice refractory patients may need on demand IVIg to temporarily increase the platelet count sufficiently to safely perform invasive procedures or in case of major bleeding or trauma; the platelet count to be reached will depend on the nature of the invasive procedure.

Corticosteroids are permitted, if the patient is on long-term stable doses, but they should not be given as a pre-treatment to alleviate potential tolerability problems. Changes in background corticosteroid medication should be avoided during the study. Patients with increases in corticosteroid...
doses during the duration of the response period of the study should be regarded as treatment failures.

The results should be compared to data from the literature, however, given that response criteria definitions have evolved, the response rate should be analysed in the context of the definition used.

**Efficacy parameters**

Number and % of patients with response (R), complete response (CR), and loss of response as well as time to response and duration of response and non-responders.

These patient parameters are defined according to the proposals of an International Working Group1:

- **Patients with R:** platelet count \( >30 \times 10^9/l \) and at least 2-fold increase of the baseline count, confirmed on at least 2 separate occasions at least 7 days apart, and absence of bleeding.

- **Patients with CR:** platelet count \( >100 \times 10^9/l \), confirmed on at least 2 separate occasions at least 7 days apart, and absence of bleeding.

- **Patients with loss of CR or R:** platelet count below \( 100 \times 10^9/l \) or bleeding (from CR) or below \( 30 \times 10^9/l \) or less than 2-fold increase of baseline platelet count or bleeding (from R). Platelet counts confirmed on at least 2 separate occasions approximately 1 day apart.

- **Time to response:** time from starting treatment to time of achievement of CR or R (late responses not attributable to the investigated treatment should not be defined as CR or R).

- **Duration of response:** measured from the achievement of CR or R to loss of CR or R.

- **Non-responder:** a patient who does not achieve a Response.

**Statistical considerations**

- Wherever possible, platelet parameters should be provided as mean (and standard deviation) and median (and minimum and maximum) values for each patient, as well as for summary data.

5.3.4. **Measles pre-/post exposure prophylaxis**

If the minimum measles antibody potency specification threshold of \( 0.36 \times \) Center for Biologics Evaluation and Research (CBER) Standard is met and added to the product specification, the indication "measles pre-/post exposure prophylaxis" as specified in the core SmPC could be added to the product information (FDA, 2018).

5.3.5. **Guillain-Barré syndrome (GBS), Kawasaki’s disease, Multifocal motor neuropathy (MMN), Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)**

If the efficacy in primary immunodeficiency syndromes and in ITP is established, then an extrapolation to GBS, Kawasaki’s disease, MMN and CIDP might be possible without the need to perform separate clinical trials in these indications, if adequately justified.

The dosage regimen should however be justified. If other dosage regimens than the ones provided in the guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg) are requested, they should be supported by relevant clinical data.
5.3.6. Other indications

Other possible indications cannot be granted without relevant clinical data. Biological and pharmacokinetic data alone are not sufficient to support demonstration of clinical efficacy.

The required extent of clinical data and the type of trial design may vary according to the proposed indication(s), thus, it is recommended to seek Scientific Advice.

5.4. Safety

Product safety is evaluated based on all pertinent safety findings. A comprehensive risk management plan (RMP) has to be submitted as part of the dossier.

5.5. Adverse events

All adverse events (AE) in clinical studies must be recorded and analysed with regards to causality, seriousness, outcome and expectedness.

Safety data from trials in indications not claimed in the application can be used as supportive data.

Comprehensive baseline data and patient histories are essential to compare the safety signals arising from the studies. The safety signals should be compared with data and frequencies described in the literature. Any deviation from known signals and rates with existing IVIG should be discussed (See Section 4.8 of the core SmPC for IVIGs for relevant adverse reactions). Adverse events and serious adverse events (SAEs) from all patients followed throughout the clinical studies should be recorded and reported regardless of whether the AE is determined to be related to the product or not.

Safety evaluation should also include monitoring of short-term tolerance at repeated intervals following the infusion of the new product. All AEs that begin during or within 72 hours after an infusion should be classified and analysed as infusional AEs.

AEs should be evaluated with regard to the dose of the IVIG course and infusion rates. Renal function should be monitored, particularly in patients at risk and in those receiving high doses of IVIg.

All safety data should include a separate evaluation of the safety dataset in children and adolescents. This should be compared to the adult dataset and relevant discrepancies listed in the SmPC.

Post-marketing safety data collection in children should be proposed in the risk management plan.

A separate safety evaluation of the excipients should be provided, which should encompass a summary of the non-clinical and literature data.

5.6. Safety with respect to transmissible agents

Compliance with CHMP recommendations (EMA/CHMP/BWP/360642/2010 rev. 1) with regards to viral safety and other transmissible agents is necessary for all plasma-derived medicinal products and is verified by information supplied in Module 3 of the dossier.

A pre-treatment serum sample from each patient included in the clinical trials should be stored at -70°C for possible future testing.

5.6.1. Viral Safety

Manufacturers of plasma-derived medicinal products, including IVIg, are required to optimise viral safety by selection of donors, screening of individual donations and plasma pools for specific markers.
of infection and the inclusion of effective steps for the inactivation/removal of viruses in the manufacturing processes. The above-mentioned procedures are now considered to be highly effective and demonstrative of the viral safety of the product with respect to enveloped viruses.

These procedures may be of limited value against non-enveloped viruses, such as hepatitis A virus and parvovirus B19. There is reassuring clinical experience regarding the lack of hepatitis A or parvovirus B19 transmission with immunoglobulins and it is also assumed that the antibody content makes an important contribution to the viral safety.

The applicant is nevertheless required to provide all available data gathered on patients treated with the product in clinical trials. Investigators should continue with their normal clinical practice of monitoring patients. The applicant should demonstrate that there are systems in place to collect information on patients treated with the product and to respond rapidly to any reports of infection with a full investigation.

For products with an entirely novel manufacturing process other principles may apply. These applications should be discussed with the Regulatory Authorities prior to submission.

5.6.2. Other transmissible agents

Similar principles to those outlined above for viral safety apply to safety with regards to other transmissible agents including Transmissible Spongiform Encephalopathy and other emerging pathogens. As of the finalisation of this guideline, no transmissions of prions have been reported with use of IVIG products.

Manufacturers should follow the respective guidance documents and position statements.

5.6.3. Other safety issues

The effect of passive transmission of haemagglutinins and haemolysins (anti-A/anti-B), and anti-D should be evaluated in patients receiving high doses of IVIg, by searching for haemolysis and performing a Direct Antiglobulin Test (DAT; direct Coombs’ test) in the patient.

5.7. Studies in paediatric patients

Where a paediatric investigation plan is required to comply with Paediatric Regulation (EC) No 1901/2006, the applicant should provide a plan that includes the recommendations described in this guideline for the paediatric population.

6. Change in the manufacturing process of authorised products

Changes in the manufacturing procedures may lead to significant changes in the product and may thereby alter the structure of the immunoglobulin and/or its activity or the safety of the product.

6.1. General aspects

When a change is introduced to the manufacturing process of a given product, the marketing authorisation holder will have to demonstrate that the “post-change” and the “pre-change” product are comparable in terms of quality, safety and efficacy. This will be a sequential process, beginning with investigations of quality and supported, as necessary, by non-clinical and/or clinical studies.
The extent of clinical data to be provided has to be judged on a case-by-case basis depending on the anticipated impact of the changes and could vary from a pharmacokinetic trial comparing “pre-change” versus “post-change” product up to the full clinical data set as outlined for a new product.

As a consequence, applications should be accompanied by assessment of the potential impact of a change on efficacy and safety of a given product and the rationale behind the clinical development plan should be outlined and justified.

If a significant impact on the activity of the immunoglobulin cannot be excluded, data on pharmacokinetics and safety in PID patients is required. In addition, since the biological rationale for efficacy in ITP is not completely elucidated, efficacy and safety in ITP patients should also be provided with the application.

If the biological data and/or pharmacokinetics data are substantially different from the parent preparation, then the product should comply with the requirements for a new product as defined in section 5.

6.2. Biological data

The effects of changes in the manufacturing process (e.g. viral inactivation steps, changes in pH, changes of excipients, changes in dimer content or new purification procedures) on the biological characteristics and activity of the product should be investigated.

Thus, it is important to provide full data on antibody integrity and function as for new products (see section 5.1).

6.3. Pharmacokinetics

Plasma concentration-time curve, half-life, area under the curve, volume of distribution, Cmax, Tmax, and elimination rate constant(s) should be measured in adult PID patients assessed by repeated blood sampling after approximately 5–6 administrations of the product until immediately before the next infusion. These PK parameters should be compared to data obtained with the predecessor product, whereby predefined comparability limits and the sample size should be justified by the applicant.

6.4. Efficacy and safety

For ITP, since the biological rationale for efficacy is not completely elucidated, a further clinical study is required as outlined above in 5.3.3.

The remaining indications that were granted for the parent product (i.e. prior to the changes in the manufacturing procedures) can be granted by reference to the literature, provided that efficacy has been established in ITP for the modified product.

PID patients included in the limited PK study (5.2) and ITP patients should be evaluated for safety according to the principles outlined in 5.4.

Requirements for viral safety and other transmissible agents are the same as for the parent product (see 5.4.2).

Should the indication “measles pre-/post exposure prophylaxis” be sought, the requirements for anti-measles antibody titre threshold would be the same as for the parent product (see 5.3.4).
7. References


Definitions

CIDP  Chronic inflammatory demyelinating polyradiculoneuropathy
GBS  Guillain-Barré Syndrome
ITP  Primary immune thrombocytopenia
MMN  Multifocal motor neuropathy
PID  Primary Immunodeficiencies
SID  Secondary immunodeficiency
IVIg  Human normal immunoglobulin for intravenous administration
AE  adverse event
SAE  serious adverse event
PK  pharmacokinetics
ADCC  antibody-dependent cell-mediated cytotoxicity
PSAF  proven specific antibody failure
IgG  immunoglobulin G
Tss  time to steady-state
R  response
CR  complete response
NR  non-responder